Interestingly, pre-human studies have suggested that glutamatergic NMDA-mediated neurotransmission may be involved in the pathophysiology of Alzheimer’s disease, also modulating the formation of amyloid and tau protein aggregates [39]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.